Medical specialists from Japan tagged as investigators in clinical trials studying Carcinoma, Non-Small-Cell Lung

Total 69 results

Akihiro Tamiya
Seen in:
- Osaka, Sakai-Shi, National Hospital Organization Kinki-Chuo Chest Medical Center
Trials:
- NCT05973773 (Principal Investigator)
Conditions:
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Haruhiro Saito
Seen in:
- Yokohama-shi, Kanagawa Cancer Center
Trials:
- NCT05882734 (Principal Investigator)
Conditions:
- Non-Small Cell Lung Cancer
Haruki Kobayashi
Seen in:
- Shizuoka, Nagaizumi-cho,Sunto-gun, Tominaga Hospital
Trials:
- NCT06119581 (Principal Investigator)
Conditions:
- Carcinoma, Non-Small-Cell Lung;
- Neoplasm Metastasis
Haruko Daga
Seen in:
- Osaka, Osaka City General Hospital
Trials:
- NCT03906331 (Principal Investigator)
- NCT03157128 (Principal Investigator)
- NCT05973773 (Principal Investigator)
Conditions:
Haruyasu Murakami
Seen in:
- Shizuoka, Shizuoka Cancer Center
- Shizuoka-Ken, Sunto-gun, Shizuoka Cancer Center
Trials:
- NCT05765734 (Principal Investigator)
- NCT04036682 (Principal Investigator)
Conditions:
Haurko Daga
Seen in:
- Osaka, Osaka City General Hospital
Trials:
- NCT04036682 (Principal Investigator)
Conditions:
- Non Small Cell Lung Cancer;
- EGFR Exon 20 Mutation
Hidenobu Ishii
Seen in:
- Kurume-shi, Kurume University Hospital
Trials:
- NCT05882734 (Principal Investigator)
Conditions:
- Non-Small Cell Lung Cancer
Hidenori Kitai
Seen in:
- Hokkaido, Sapporo, Hokkaido University Hospital
Trials:
- NCT06119581 (Principal Investigator)
Conditions:
- Carcinoma, Non-Small-Cell Lung;
- Neoplasm Metastasis
Hidetoshi Hayashi
Seen in:
- Osaka, GSK Investigational Site
Trials:
- NCT05565378 (Principal Investigator)
Conditions:
- Lung Cancer, Non-Small Cell
Hiroaki Akamatsu
Seen in:
- Wakayama, Wakayama Medical University Hospital
Trials:
- NCT06119581 (Principal Investigator)
Conditions:
- Carcinoma, Non-Small-Cell Lung;
- Neoplasm Metastasis
Hiroshi Tanaka
Seen in:
- Hokkaido, GSK Investigational Site
- Hokkaido, Niigata, Niigata Cancer Center Hospital
- Niigata, Niigata Cancer Center
- Niigata, Niigata Cancer Center Hospital
- Niigata, Niigata-shi, Niigata Cancer Center Hospital
Trials:
- NCT04718389 (Principal Investigator)
- NCT04819100 (Principal Investigator)
- NCT05243680 (Principal Investigator)
- NCT04036682 (Principal Investigator)
Conditions:
Hirotsugu Kenmotsu
Seen in:
- Shizuoka, Nagaizumi, Shizuoka Cancer Center
- Shizuoka, Nagaizumi, Tominaga Hospital
- Shizuoka, Nagaizumi-cho,Sunto-gun, Shizuoka Cancer Center
- Shizuoka, Nagaizumi-cho,Sunto-gun, Tominaga Hospital
Trials:
- NCT04819100 (Principal Investigator)
- NCT03157128 (Principal Investigator)
Conditions:
Hisao Imai
Seen in:
- Saitama, Hidaka, Saitama Medical University International Medical Center
Trials:
- NCT06119581 (Principal Investigator)
Conditions:
- Carcinoma, Non-Small-Cell Lung;
- Neoplasm Metastasis
Hisashi Tanaka
Seen in:
- Aomori, Hirosaki-Shi, Hirosaki University Hospital
- Kanazawa, Kanazawa University Hospital
Trials:
- NCT05973773 (Principal Investigator)
Conditions:
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Isamu Okamoto
Seen in:
- Fukuoka, Fukuoka-shi, Kyushu University Hospital
- Fukuoka, GSK Investigational Site
- Fukuoka, Kyushu University Hospital
Trials:
- NCT05207371 (Principal Investigator)
- NCT05565378 (Principal Investigator)
- NCT06119581 (Principal Investigator)
Conditions:
Jiro Okami
Seen in:
- Osaka, Osaka International Cancer Institute
- Osaka, Osaka Medical Center for Cancer and Cardiovascular Diseases
Trials:
- NCT04819100 (Principal Investigator)
Conditions:
- Carcinoma, Non-Small-Cell Lung
Jun Sakakibara
Seen in:
- Hokkaido, Sapporo, Hokkaido University Hospital
Trials:
- NCT03906331 (Principal Investigator)
- NCT03157128 (Principal Investigator)
Conditions:
Kadoaki Ohashi
Seen in:
- Okayama, Okayama University Hospital
- Okayama, Okayamashi, Okayama University Hospital
Trials:
- NCT03157128 (Principal Investigator)
- NCT05973773 (Principal Investigator)
- NCT06119581 (Principal Investigator)
Conditions:
Kageaki Watanabe
Seen in:
- Tokyo, Bunkyō-Ku, Tokyo Metropolitan Komagome Hospital
Trials:
- NCT06119581 (Principal Investigator)
Conditions:
- Carcinoma, Non-Small-Cell Lung;
- Neoplasm Metastasis
Katsuhiko Naoki
Seen in:
- Kanagawa, Sagamihara, Kitasato University Hospital
Trials:
- NCT05973773 (Principal Investigator)
Conditions:
- Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
Keisuke Aoe
Seen in:
- Yamaguchi, Ube, National Hospital Organization Yamaguchi Ube Medical Center
Trials:
- NCT06119581 (Principal Investigator)
Conditions:
- Carcinoma, Non-Small-Cell Lung;
- Neoplasm Metastasis
Kohei Otsubo
Seen in:
- Fukuoka, Kitakyushu, Kitakyushu Municipal Medical Center
Trials:
- NCT05207371 (Principal Investigator)
Conditions:
- NSCLC;
- Cell Therapy
Koichi Azuma
Seen in:
- Fukuoka, Kurume, Kurume University Hospital
Trials:
- NCT05207371 (Principal Investigator)
Conditions:
- NSCLC;
- Cell Therapy
Koichi Goto
Seen in:
- Chiba, Kashiwa, National Cancer Center Hospital East
- Chiba-Ken, Kashiwa-shi, National Cancer Center Hospital East
Trials:
- NCT03906331 (Principal Investigator)
- NCT03157128 (Principal Investigator)
- NCT05765734 (Principal Investigator)
Conditions:
Kyoichi Kaira
Seen in:
- Saitama, GSK Investigational Site
- Saitama, Saitama Medical University International Medical Center
Trials:
- NCT03811002 (Principal Investigator)
- NCT05565378 (Principal Investigator)
Conditions:
Kyoichi Okishio
Seen in:
- Osaka, Sakai, National Hospital Organization Kinki-Chuo Chest Medical Center
Trials:
- NCT06119581 (Principal Investigator)
Conditions:
- Carcinoma, Non-Small-Cell Lung;
- Neoplasm Metastasis
Makoto Nishio
Seen in:
- Tokyo, Koto, Japanese Foundation for Cancer Research
Trials:
- NCT03157128 (Principal Investigator)
Conditions:
Masafumi Yamaguchi
Seen in:
- Fukuoka, National Hospital Organization Kyushu Cancer Center
- Hukuoka, Fukuoka-shi, Kyushu Cancer Center
Trials:
- NCT05973773 (Principal Investigator)
- NCT06119581 (Principal Investigator)
Conditions:

Clinical Trials on Carcinoma, Non-Small-Cell Lung

Sidney Kimmel Cancer Center at Thomas Jefferson...
Bristol-Myers Squibb

Completed

Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...

United States
National Cancer Institute (NCI)

Completed

A Comparison of FLT to FDG PET/CT in the Early Assessment of Chemotherapy Response in Stage IB-IIIA Resectable NSCLC

Stage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery

Stage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

Lung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7

United States, Puerto Rico
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...

United States
National Cancer Institute (NCI)

Terminated

Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...

United States
National Cancer Institute (NCI)

Active, not recruiting

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...

United States
University of Southern California
National Cancer Institute (NCI); Society of Thoracic Radiology

Active, not recruiting

Dynamic Perfusion Computed Tomography in Patients With Localized Non-small Cell Lung Cancer

Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Completed

EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma

United States

Medical specialists from Japan tagged as investigators in clinical trials studying Carcinoma, Non-Small-Cell Lung

Clinical Trials on Carcinoma, Non-Small-Cell Lung

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations